Bacteriophage Therapy Patents

Bacteriophage therapy patents cover phage-isolation/library innovations; engineered-phage innovations; cocktail/formulation innovations; and lysin/enzybiotic and delivery/regulatory innovations — with IP held by phage-therapy companies and academia (in a field using viruses to kill bacteria). WHY PHAGE THERAPY: BACTERIOPHAGES ('phages') are viruses that infect and kill BACTERIA — but not human cells — making them a natural antibacterial; with ANTIMICROBIAL RESISTANCE (AMR) rising and the antibiotic pipeline stalling, phages are a promising weapon against ANTIBIOTIC-RESISTANT 'superbug' infections where antibiotics fail; their advantages: they are exquisitely SPECIFIC (each phage kills only particular bacterial strains, sparing the beneficial microbiome — unlike broad-spectrum antibiotics that cause collateral damage), they SELF-AMPLIFY at the infection site (replicating where the bacteria are), and they can EVOLVE alongside resistant bacteria; the core IP challenge is that natural phages are NATURAL PRODUCTS (a §101/patentability problem, like other natural organisms), and phage therapy must overcome bacterial resistance and a tricky regulatory path (especially for personalized phage matching). MAJOR HOLDERS: ARMATA PHARMACEUTICALS, LOCUS BIOSCIENCES (CRISPR-enhanced phage), BIOMX, ADAPTIVE PHAGE THERAPEUTICS, plus academia and phage banks. Phage isolation/libraries, engineered phages, cocktails/formulation, lysins/enzybiotics, and delivery/regulatory are the core phage-therapy patent domains — with §101 to manage on natural phages, and engineered phages, cocktails, and lysins the strongest IP routes and whitespace.

Phage-isolation/library innovations; engineered-phage innovations; host-range innovations; and §101-aware claiming represent core phage-therapy patent domains — and the curated phage bank and (especially) engineered, non-natural phages are the foundational, high-value capabilities. PHAGE-ISOLATION / LIBRARY PATENTS: discovering, characterizing, and BANKING diverse phages against target pathogens — building a curated, characterized phage LIBRARY/BANK and the methods to isolate/screen/match phages to bacterial strains; isolation/library methods and the bank are high-value IP (a large, well-characterized phage bank is a key strategic asset and matching engine), BUT a NATURAL phage itself faces §101 (a naturally-occurring virus is a natural product — generally not patentable as a composition), so protect the bank as a trade-secret/data asset and claim METHODS and ENGINEERED phages. ENGINEERED-PHAGE PATENTS: the STRONGEST IP route — genetically MODIFYING phages to create NON-NATURAL, patentable compositions: broadening HOST RANGE (so one phage kills more strains), REMOVING toxin/lysogeny genes (safety), enhancing potency, and ARMING phages with CRISPR (Locus's approach — delivering CRISPR to kill antibiotic-resistant bacteria sequence-specifically) or payloads; engineered-phage compositions/methods are core, high-value IP (engineering both improves the therapy AND creates clearly patentable non-natural compositions that sidestep the §101 natural-product problem — the key strategic IP route). HOST-RANGE PATENTS: engineering/selecting broad or tunable host range; host-range methods are high-value IP. §101-AWARE CLAIMING: natural phages are natural products — claim ENGINEERED phages, METHODS of treatment/isolation/matching, COCKTAILS, and lysins (not the natural phage per se); §101-aware claiming is essential. Phage isolation/libraries, engineered phages, host range, and §101-aware claiming are the highest-value core IP because a curated bank plus engineered, non-natural phages claimed around §101 is exactly what makes phage therapy both effective and protectable.

Cocktail/formulation innovations; lysin/enzybiotic innovations; delivery innovations; and resistance-management/regulatory innovations represent additional phage-therapy patent domains — and combining phages, using phage enzymes, and getting therapy to patients are where coverage, patentability, and clinical value grow. COCKTAIL / FORMULATION PATENTS: combining MULTIPLE phages into a defined COCKTAIL to BROADEN coverage (hit more strains of a pathogen) and PREVENT RESISTANCE (bacteria rarely resist several different phages at once); a specific, defined phage COCKTAIL COMPOSITION is core, high-value IP (a cocktail is a non-obvious, defined composition that's more patentable than a single natural phage and is central to efficacy and resistance prevention — a key product format). LYSIN / ENZYBIOTIC PATENTS: using phage-derived LYSINS/ENDOLYSINS — enzymes phages use to BURST bacterial cell walls — as standalone PROTEIN antibiotics ('enzybiotics'); engineered/recombinant lysins are often EASIER to patent (as engineered protein compositions), manufacture, and develop (as conventional protein drugs) than whole live phages; lysin/enzybiotic compositions/engineering are high-value, distinctive IP (lysins offer a more conventional, patentable, developable drug path — a strong alternative or complement to whole-phage therapy). DELIVERY PATENTS: formulating and DELIVERING phages/lysins stably to the infection site (oral, topical, inhaled, IV; stabilization; overcoming the body's clearance/immune response); delivery/formulation methods are high-value IP. RESISTANCE-MANAGEMENT / REGULATORY PATENTS: managing/predicting phage resistance, and addressing the REGULATORY path — including PERSONALIZED phage matching (selecting phages for an individual patient's infection), which doesn't fit standard one-drug-for-all approval and needs novel frameworks/diagnostics; resistance/regulatory-enabling methods are high-value IP (the personalized model is both a clinical strength and a regulatory/IP challenge). Cocktails/formulation, lysins/enzybiotics, delivery, and resistance-management/regulatory are the highest-value application IP because defined cocktails, patentable lysins, stable delivery, and a workable regulatory path are exactly what make phage therapy a viable product.

Phage therapy startup IP strategy must navigate the §101 natural-product problem (natural phages are natural products and generally not patentable as compositions — the central IP constraint), the engineering-is-the-IP-route reality (ENGINEERED phages, CRISPR-armed phages, defined COCKTAILS, and LYSINS create non-natural, patentable compositions that sidestep §101 — the strongest IP strategy), the Armata/Locus/BiomX/Adaptive portfolios, the bank-as-trade-secret angle (a curated phage library/bank is a key asset often best protected as trade-secret/data rather than patented), the cocktail-and-lysin patentability advantage (defined cocktails and engineered lysins are more patentable and developable than single live phages), the personalized-vs-product regulatory tension (personalized phage matching is clinically powerful but doesn't fit standard drug approval — defined cocktails/lysins are more product-like and approvable), the AMR tailwind (urgent unmet need, regulatory incentives for antibacterials), and a landscape where engineered phages, cocktails, lysins, banks, and delivery are the durable assets; understand that natural phages fail §101, so the durable IP is in engineered/CRISPR-armed phages, defined cocktail compositions, engineered lysins, isolation/matching methods, and delivery — with engineering, the cocktail/lysin formats, the phage bank (trade-secret), and clinical/regulatory progress often the real moat, and that efficacy/resistance-prevention, patentable format, regulatory path, and §101 matter as much as patents; identify whitespace in engineered/CRISPR phages, cocktails, and lysins. PHAGE THERAPY STARTUP IP STRATEGY: ENGINEERED PHAGES, COCKTAILS, LYSINS, BANKS, AND DELIVERY ARE THE IP: patent engineered/CRISPR-armed phages, defined cocktail compositions, engineered lysins/enzybiotics, isolation/matching methods, and delivery — and protect the phage bank as trade-secret/data; §101 IS THE CENTRAL CONSTRAINT (NATURAL PHAGES = NATURAL PRODUCTS): a naturally-occurring phage is generally unpatentable as a composition — don't rely on natural-phage composition claims; ENGINEERING IS THE STRONGEST IP ROUTE: genetically modified phages (broadened host range, toxin removal, CRISPR-arming — Locus) are NON-NATURAL, patentable compositions that also improve the therapy — the key strategy around §101; COCKTAILS ARE PATENTABLE + PREVENT RESISTANCE: a defined multi-phage COCKTAIL is a non-obvious composition (more patentable than a single natural phage) and prevents resistance + broadens coverage — a core product format; LYSINS/ENZYBIOTICS ARE A MORE CONVENTIONAL, PATENTABLE PATH: engineered phage-derived lysins are easier to patent, manufacture, and develop as protein drugs — a strong alternative/complement; THE PHAGE BANK IS A TRADE-SECRET ASSET: a curated, characterized phage library/matching engine is a key asset often best protected as trade-secret/data; PERSONALIZED VS PRODUCT IS THE REGULATORY TENSION: personalized phage matching is powerful but unfits standard approval — defined cocktails/lysins are more product-like/approvable; AMR TAILWIND DRIVES NEED/INCENTIVES: urgent resistance crisis + antibacterial regulatory incentives support the field; EFFICACY/FORMAT/REGULATORY/§101 MATTER AS MUCH AS PATENTS: efficacy/resistance-prevention, patentable format, regulatory path, and §101 drive value; WHEN TO PATENT (OR KEEP SECRET): NOVEL ENGINEERED-PHAGE/COCKTAIL/LYSIN WITH MEASURED DATA: file (or trade-secret the bank) once a candidate shows measured results (bacterial killing/host range + resistance prevention (cocktail) + (engineered) non-natural composition + lysin potency + in vivo efficacy + safety) — measured killing, host range/resistance prevention, and a patentable engineered/cocktail/lysin format are the critical phage IP metrics; KEY FTO CHECKLIST: Armata/Locus (CRISPR phage)/BiomX/Adaptive Phage; §101 natural-product (claim engineered/method/cocktail/lysin, not natural phage); phage isolation/library/bank (trade-secret + matching methods); engineered phage (host range/toxin removal/CRISPR-armed/payload); cocktail/formulation (defined multi-phage composition, resistance prevention); lysin/enzybiotic (engineered/recombinant endolysin protein drug); delivery (oral/topical/inhaled/IV, stabilization, immune clearance); resistance-management; regulatory (personalized matching vs defined-product approval); AMR incentives.